Document Detail

Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease.
MedLine Citation:
PMID:  19176795     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND OBJECTIVES: Chronic kidney disease (CKD) has recently assumed epidemic proportion, becoming a troubling emerging cause of morbidity, especially if it progresses to terminal stage (ESRD). The authors aimed to evaluate whether neutrophil gelatinase-associated lipocalin (NGAL), a novel specific biomarker of acute kidney injury, could predict the progression of CKD.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Serum and urinary NGAL levels, together with a series of putative progression factors, were evaluated in a cohort of 96 patients (mean age: 57 +/- 16 years) affected by nonterminal CKD (eGFR > or =15 ml/min/1.73 m(2)) of various etiology. Progression of CKD, assessed as doubling of baseline serum creatinine and/or onset of ESRD, was evaluated during follow-up.
RESULTS: At baseline, both serum and urinary NGAL were inversely, independently, and closely related to eGFR. After a median follow-up of 18.5 mo (range 1.01 to 20), 31 patients (32%) reached the composite endpoint. At baseline, these patients were significantly older and showed increased serum creatinine, calcium-phosphate product, C-reactive protein, fibrinogen, daily proteinuria, and NGAL levels, whereas eGFR values were significantly lower. Univariate followed by multivariate Cox proportional hazard regression analysis showed that urinary NGAL and sNGAL predicted CKD progression independently of other potential confounders, including eGFR and age.
CONCLUSION: In patients with CKD, NGAL closely reflects the entity of renal impairment and represents a strong and independent risk marker for progression of CKD.
Davide Bolignano; Antonio Lacquaniti; Giuseppe Coppolino; Valentina Donato; Susanna Campo; Maria Rosaria Fazio; Giacomo Nicocia; Michele Buemi
Related Documents :
18635215 - Validation of the fournier's gangrene severity index in a large contemporary series.
18598995 - Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.
17875185 - Circulating e-selectin as a risk marker in patients with end-stage renal disease.
19782835 - Cardiac screening before noncardiac surgery.
20405 - Complement levels in pneumococcal pneumonia.
15137605 - Is the placement of shunts in patients with idiopathic normal-pressure hydrocephalus wo...
Publication Detail:
Type:  Journal Article     Date:  2009-01-28
Journal Detail:
Title:  Clinical journal of the American Society of Nephrology : CJASN     Volume:  4     ISSN:  1555-905X     ISO Abbreviation:  Clin J Am Soc Nephrol     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-02-16     Completed Date:  2009-06-11     Revised Date:  2013-06-02    
Medline Journal Info:
Nlm Unique ID:  101271570     Medline TA:  Clin J Am Soc Nephrol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  337-44     Citation Subset:  IM    
Department of Internal Medicine, University of Messina, Messima, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute-Phase Proteins / urine*
Biological Markers / blood,  urine
Chronic Disease
Creatinine / blood
Disease Progression
Glomerular Filtration Rate
Kaplan-Meier Estimate
Kidney Diseases / complications,  metabolism*,  physiopathology
Kidney Failure, Chronic / blood,  etiology*,  physiopathology
Lipocalins / blood*,  urine*
Middle Aged
Predictive Value of Tests
Proportional Hazards Models
Prospective Studies
Proto-Oncogene Proteins / blood*,  urine*
ROC Curve
Risk Assessment
Risk Factors
Reg. No./Substance:
0/Acute-Phase Proteins; 0/Biological Markers; 0/LCN2 protein, human; 0/Lipocalins; 0/Proto-Oncogene Proteins; 60-27-5/Creatinine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The costs and benefits of automatic estimated glomerular filtration rate reporting.
Next Document:  Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.